Pharmaceutical

FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer

ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.

Feb 21, 2025 - 06:00
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.
Read the original article

Tags:

Previous Article

WHO targets over half a million children in Gaza for polio vaccine drive

Next Article

Pharma and medtech industry reacts to FDA, CDC and NIH job cuts

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

M&A market performance suffered in Q3 2023

M&A market performance suffered in Q3 2023

Oct 31, 2023

STAT+: FDA official pushes for a dedicated emerging pathogens team to prepare for the next pandemic

STAT+: FDA official pushes for a dedicated emerging pat...

Jul 22, 2023

Atypical Teratoid Rhabdoid Tumor drugs in development, ...

Aug 31, 2024